BPC 157 Pure The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide The FDA will hold a meeting to consider easing restrictions on more than a half dozen peptide injections, a group of unapproved therapies that have become popular among wellness influencers, fitness gurus